Literature DB >> 8486933

Optimization of a time-resolved immunofluorometric assay for tumor-associated trypsin inhibitor (TATI) using the streptavidin-biotin system.

S Osman1, U Turpeinen, O Itkonen, U H Stenman.   

Abstract

We have developed two 'sandwich'-type time-resolved immunofluorometric assays (IFMA) for tumor-associated trypsin inhibitor (TATI) using monoclonal and polyclonal antibodies. In the standard assay the monoclonal antibody was immobilized onto the walls of polystyrene microstrip wells and the polyclonal reagent was labeled with a europium chelate. We tested various assay conditions in order to optimize the assay for sensitivity and measuring range. Purification of the labeled antibody by hydrophobic interaction chromatography was found to be the most important single factor affecting sensitivity. Assay sensitivity and range were also improved by acid treatment of the solid phase antibody. To improve the sensitivity further the streptavidin/biotin (SAB) system was incorporated into the IFMA technique. In this simple and fast streptavidin/biotin IFMA (SAB-IFMA) we used streptavidin-coated wells to which we added biotinylated monoclonal antibody and a serum or urine sample. After incubation for 1.5 h and washing, the polyclonal europium-labeled tracer antibody was added. After incubation for 1 h the wells were washed and the Eu fluorescence measured. The assay performance of the SAB-IFMA was compared to the standard IFMA and radioimmunoassay (RIA). The detection limit was 0.05 microgram/l and the analytical range 3000-fold. The mean analytical recovery was 101%. Other advantages of the SAB-IFMA were high sensitivity and the low amounts of monoclonal antibody required, only 1/50 of that used in the standard IFMA.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8486933     DOI: 10.1016/0022-1759(93)90201-h

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  10 in total

1.  Association of tumor-associated trypsin inhibitor (TATI) expression with molecular markers, pathologic features and clinical outcomes of urothelial carcinoma of the urinary bladder.

Authors:  Oliver Patschan; Shahrokh F Shariat; Daher C Chade; Pierre I Karakiewicz; Raheela Ashfaq; Yair Lotan; Kristina Hotakainen; Ulf-Håkan Stenman; Anders Bjartell
Journal:  World J Urol       Date:  2011-07-08       Impact factor: 4.226

2.  Low trypsinogen-1 expression in pediatric ulcerative colitis patients who undergo surgery.

Authors:  Maija Piekkala; Jaana Hagström; Maarit Tanskanen; Risto Rintala; Caj Haglund; Kaija-Leena Kolho
Journal:  World J Gastroenterol       Date:  2013-06-07       Impact factor: 5.742

3.  Trypsin-2 degrades human type II collagen and is expressed and activated in mesenchymally transformed rheumatoid arthritis synovitis tissue.

Authors:  Mathias Stenman; Mari Ainola; Leena Valmu; Anders Bjartell; Guofeng Ma; Ulf-Håkan Stenman; Timo Sorsa; Reijo Luukkainen; Yrjö T Konttinen
Journal:  Am J Pathol       Date:  2005-10       Impact factor: 4.307

4.  Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer.

Authors:  Katri A Leinonen; Outi R Saramäki; Bungo Furusato; Takahiro Kimura; Hiroyuki Takahashi; Shin Egawa; Hiroyoshi Suzuki; Kerri Keiger; Sung Ho Hahm; William B Isaacs; Teemu T Tolonen; Ulf-Håkan Stenman; Teuvo L J Tammela; Matti Nykter; G Steven Bova; Tapio Visakorpi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-10-01       Impact factor: 4.254

5.  The role of SPINK1 in ETS rearrangement-negative prostate cancers.

Authors:  Scott A Tomlins; Daniel R Rhodes; Jianjun Yu; Sooryanarayana Varambally; Rohit Mehra; Sven Perner; Francesca Demichelis; Beth E Helgeson; Bharathi Laxman; David S Morris; Qi Cao; Xuhong Cao; Ove Andrén; Katja Fall; Laura Johnson; John T Wei; Rajal B Shah; Hikmat Al-Ahmadie; James A Eastham; Scott E Eggener; Samson W Fine; Kristina Hotakainen; Ulf-Håkan Stenman; Alex Tsodikov; William L Gerald; Hans Lilja; Victor E Reuter; Phillip W Kantoff; Peter T Scardino; Mark A Rubin; Anders S Bjartell; Arul M Chinnaiyan
Journal:  Cancer Cell       Date:  2008-06       Impact factor: 31.743

6.  Effects of radiation therapy on tissue and serum concentrations of tumour associated trypsin inhibitor and their prognostic significance in rectal cancer patients.

Authors:  Alexander Gaber; Christina Stene; Kristina Hotakainen; Björn Nodin; Ingrid Palmquist; Anders Bjartell; Ulf-Håkan Stenman; Bengt Jeppsson; Louis B Johnson; Karin Jirström
Journal:  Radiat Oncol       Date:  2011-08-24       Impact factor: 3.481

7.  The levels of trypsinogen isoenzymes in ovarian tumour cyst fluids are associated with promatrix metalloproteinase-9 but not promatrix metalloproteinase-2 activation.

Authors:  A Paju; T Sorsa; T Tervahartiala; E Koivunen; C Haglund; A Leminen; T Wahlström; T Salo; U H Stenman
Journal:  Br J Cancer       Date:  2001-05-18       Impact factor: 7.640

8.  A high-density tissue microarray from patients with clinically localized prostate cancer reveals ERG and TATI exclusivity in tumor cells.

Authors:  G Lippolis; A Edsjö; U-H Stenman; A Bjartell
Journal:  Prostate Cancer Prostatic Dis       Date:  2013-03-05       Impact factor: 5.554

9.  High expression of tumour-associated trypsin inhibitor correlates with liver metastasis and poor prognosis in colorectal cancer.

Authors:  A Gaber; M Johansson; U-H Stenman; K Hotakainen; F Pontén; B Glimelius; A Bjartell; K Jirström; H Birgisson
Journal:  Br J Cancer       Date:  2009-04-21       Impact factor: 7.640

10.  MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma.

Authors:  Kati Räsänen; Kien X Dang; Harri Mustonen; Tho H Ho; Susanna Lintula; Hannu Koistinen; Ulf-Håkan Stenman; Caj Haglund; Jakob Stenman
Journal:  Mol Oncol       Date:  2017-12-27       Impact factor: 6.603

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.